Meeting
2020 Genitourinary Cancers Symposium
Determination of the ability of a novel, long-acting subcutaneous GnRH antagonist, VERU-100, to castrate without a testosterone surge in a rat model.
Authors
Robert H. Getzenberg
Veru Inc, Miami, FL
Robert H. Getzenberg , Jui-Chen Lin , Andrew Cerro , Christopher A. Rhodes , Mitchell S. Steiner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 128)
Abstract #
128
Poster Bd #
F8
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy (iADT) with relugolix.
First Author: Patrick Campbell
Poster
2014 Genitourinary Cancers Symposium
Optimal testosterone suppression on medical ADT should strive to suppress free testosterone levels to levels similar to orchiectomy: What is that value?
First Author: Evan Y. Yu
Poster
2013 Genitourinary Cancers Symposium
Effect of Gtx-758, an ERα agonist, on serum-free testosterone and serum PSA in men with advanced prostate cancer.
First Author: Evan Y. Yu
Poster
2012 Genitourinary Cancers Symposium
Testosterone suppression: Impact of testosterone level on disease progression in advanced prostate cancer.
First Author: Shawn Dason